Turku Bioscience group leader, Professor Klaus Elenius, is the new scientific director of BioCity Turku for the next five years. He will also be the Read more
Signs of type 1 diabetes might be detectable in blood already years before clinical symptoms (Dissertation: M. Sc. Essi Laajala, December 17th 2021, medical microbiology Read more
Special Guest Seminar 16.12.2021 at 18 – 19 President auditorium, Visitor and Innovation Centre Joki, BioCity Hybrid event, a Zoom link will be available for Read more
Immunology Seminar December 7 at 14-15 Virtual event Flyer Tuure Kinnunen, University of Eastern Finland: T cell studies in type 1 diabetes Host: Riitta Lahesmaa Read more
CIP2A regulates T cell functions Doctoral dissertation: MSc Mohd Moin Khan, 3.12.2021, Medical microbiology and immunology In his doctoral dissertation research at the University of Read more
Prof. Jukka Westermarck and his reserach group received Cancer Foundation funding of 300 000 € for the work elucidating the novel role of oncoprotein CIP2A Read more
We are proud to announce that The Cancer Foundation Finland – the largest private funder of cancer research in Finland – has awarded grants to Read more
November 18th at 12:00 Virtual event Frontiers of Science meets InFLAMES Prof. Janne Lehtiö, Karolinska Institutet, Sweden Cancer molecular phenotyping – Leukemia proteomics defined high Read more
On 1-5 November, we had a TET-trainee (workplace practice program for junior high school students) Eveliina Lähdesmäki at Westermarck Lab. During these five days, she Read more
Immunology Seminar November 23 at 14-15 Virtual event Flyer Riitta Veijola, University of Oulu and Oulu University Hospital Type 1 Diabetes Prediction and Prevention (DIPP) Read more
From left to right: Dr. Alex M Dickens*, Dr. Partho Sen*, Dr. Syed Bilal Ahmad Andrabi+ and Dr. Tanja Buchacher+. ‘*’ represents Systems Medicine group Read more
Last updated on June 25, 2025
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
